|Application ||WB, IF, E|
|Other Accession||NP_000067, 4557441|
|Calculated MW||35 kDa|
|Application Notes||CDKN1C antibody can be used for detection of CDKN1C by Western blot at 1 - 2 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Target/Specificity||CDKN1C; At least three isoforms of CDKN1C are known to exist; this antibody will detect all three isoforms. Despite its predicted molecular weight, CDKN1C often migrates at 57kDa in SDS-PAGE. CDKN1C antibody is predicted to not cross react with other CIP/KIP proteins.|
|Reconstitution & Storage||CDKN1C antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||CDKN1C Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. Negative regulator of cell proliferation. May play a role in maintenance of the non- proliferative state throughout life.|
|Tissue Location||Expressed in the heart, brain, lung, skeletal muscle, kidney, pancreas and testis. Expressed in the eye. High levels are seen in the placenta while low levels are seen in the liver.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CDKN1C Antibody: The cyclin-dependent kinase inhibitor 1C (CDKN1C), also known as p57KIP2, is a tight-binding, strong inhibitor of several G1 cyclin/CDK complexes and a negative regulator of cell proliferation. Mutations in this gene are implicated in sporadic cancers and Beckwith-Wiedemann syndrome, a cancer-predisposing syndrome, suggesting that this gene is a tumor suppressor candidate. CDKN1C is widely expressed during organogenesis with its expression declining after maturity. It is part of the CIP/KIP family of cyclin-dependent inhibitors (CKIs) which also includes CDKN1A and CDKN1B.
Lee MH, Reynisdottir I, and Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 1995; 9:639-49.
Pateras IS, Apostolopoulou K, Niforou K, et al. p57KIP2: “Kip"ing the cell under control. Mol. Cancer Res. 2009; 1902-19
Hatada I, Ohashi H, Fukushima Y, et al. An imprinted p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat. Genet. 1996; 14:171-3.
If you have any additional inquiries please email technical services at email@example.com.